- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- Guanfacine hydrochloride (TAK-503), Atomoxetine hydrochloride, Placebo
- Drug · Other
- Lead sponsor
- Shire
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 396 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 20
- States / cities
- Dothan, Alabama • Anaheim, California • Imperial, California + 17 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–8
of 8
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Healthy
- Interventions
- SPD503, Concerta, SPD503 + Concerta
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- Hackensack, New Jersey
- Conditions
- ADHD
- Interventions
- SPD503-AM, SPD503-PM, Placebo
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 461 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 61
- States / cities
- Dothan, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 53 more
- Conditions
- ADHD
- Interventions
- SPD503 (Guanfacine hydrochloride), Placebo
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 6 Years to 12 Years
- Enrollment
- 217 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 34
- States / cities
- Phoenix, Arizona • El Centro, California • Rolling Hills Estates, California + 29 more
- Conditions
- Attention-Deficit/Hyperactivity Disorder, Attention Deficit Disorder, Insomnia, Sleep Disorders
- Interventions
- Guanfacine extended-release tablets, Placebo comparator
- Drug
- Lead sponsor
- Children's Specialized Hospital
- Other
- Eligibility
- 6 Years to 12 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 2
- States / cities
- Hamilton, New Jersey • Toms River, New Jersey
- Conditions
- Healthy
- Interventions
- SPD503, VYVANSE, SPD503 and VYVANSE
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- Hackensack, New Jersey
- Conditions
- Attention-Deficit/Hyperactivity Disorder
- Interventions
- extended-release guanfacine hydrochloride (SPD503), placebo, extended-release guanfacine hydrochloride
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 6 Years to 12 Years
- Enrollment
- 340 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 42
- States / cities
- Little Rock, Arkansas • El Centro, California • Rolling Hills Estates, California + 38 more
- Conditions
- Generalized Anxiety Disorder (GAD), Anxiety, Separation, Phobia, Social
- Interventions
- SPD503 (extended-release Guanfacine hydrochloride), Placebo
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 33
- States / cities
- Birmingham, Alabama • Carson, California • Imperial, California + 29 more